[1] Trifan A, Stratina E, Rotaru A, et al. Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis C infection treated with direct-acting antivirals therapy who achieved sustained virological response. Diagnostics, 2022, 12(3): 702.
[2] Cunha-Silva M, Torres L D, Fernandes M F, et al. Changes in indications for outpatient percutaneous liver biopsy over 5 years: from hepatitis C to fatty liver disease. Gastroenterol Hepatol, 2021,17(12):S0210-5705(21)00328-9.
[3] Chaudhari R, Fouda S, Sainu A, et al. Metabolic complications of hepatitis C virus infection. World J Gastroenterol,2021,27(13):1267-1282.
[4] Benhammou J N, Moon A M, Pisegna J R, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. Dig Dis Sci,2021,66(7):2394-2406.
[5] Vieyres G, Reichert I, Carpentier A, et al. The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. PLoS Pathog,2020,16(6):e1008554.
[6] Sigon G, D'Ambrosio R, Clerici M, et al. Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver Int, 2019,39(12):2309-2316.
[7] Campana B, Calabrese D, Matter M S, et al. In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections. J Viral Hepat,2018,25(3):262-271.
[8] Miyaaki H, Miuma S, Taura N, et al. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C. Hepatol Res,2018,48(3):E335-E339.
[9] Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther,2020,51(2):216-230.
[10] Valkov I, Ivanova R, Alexiev A, et al. Association of serum lipids with hepatic steatosis, stage of liver fibrosis and viral load in chronic hepatitis C. J Clin Diagn Res,2017,11(8):OC15-OC20.
[11] Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, et al. Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C. BMC Infect Dis,2017,17(1):361.
[12] Basaranoglu M, Canbakan B, Yildiz K, et al. Nonalcoholic fatty liver may increase the risk of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives. Turk J Gastroenterol,2014,25(1):138-141.
[13] Sagnelli C, Merli M, Uberti-Foppa C, et al. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. World J Gastroenterol,2016,22(38):8509-8518.
[14] Nishida N, Kudo M. Clinical features of vascular disorders associated with chronic hepatitis virus infection. Dig Dis,2014,32(6):786-790.
[15] Loy M, Serra G, Chessa L. The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. J Ultrasound,2014,19(2):91-98.
[16] Aguilar M, Liu B, Holt E W, et al. Impact of obesity and diabetes on waitlist survival, probability of liver transplantation and post-transplant survival among chronic hepatitis C virus patients. Liver Int,2016,36(8):1167-1175.
[17] Fan JH, Xiang MQ, Li QL, et al. PNPLA3 rs738409 polymorphism associated with hepatic steatosis and advanced fibrosis in patients with chronic hepatitis C virus: a meta-analysis. Gut Liver, 2016,10(3):456-463.
[18] Wong RJ, Gish RG. Metabolic manifestations and complications associated with chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y),2016,12(5):293-299.
[19] Sagnelli C, Merli M, Uberti-Foppa C, et al. Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C. Clin Microbiol Infect,2016,22(4):372-378.
[20] Dyal HK, Aguilar M, Bartos G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Dig Dis Sci,2016,61(2):636-645.
[21] 王艳斌,范颖,谢雯.非酒精性脂肪性肝病与丙型肝炎.中国临床医生杂志,2020,48(01):10-12.
[22] 董金玲,谢志宏,何杰,等.慢性丙型肝炎合并脂肪肝患者Sirt1和固醇调节元件结合蛋白表达及意义.中华实验和临床感染病杂志(电子版),2018,12(06):577-584.
[23] 靳镝.重组人干扰素α2a联合利巴韦林治疗慢性丙型肝炎合并脂肪肝的效果.中国当代医药,2018,25(33):59-61.
[24] 李竞,缪萍,黄涓涓,等.调脂合剂对慢性丙型肝炎病毒感染合并脂肪肝患者脂质代谢紊乱的影响.中华实验和临床病毒学杂志,2018,32(05):525-528.
[25] 兰静,曹彦丙.慢性丙型肝炎合并非酒精性脂肪肝血清尿酸与病毒及代谢的相关分析.实用医技杂志,2018,25(09):952-954.
[26] 李园园,周俊英.慢性丙型肝炎与肝脏脂肪变性.现代医药卫生,2017,33(20):3073-3075.
[27] 张秀丽.ALT与AST比值预测慢性丙型肝炎患者肝脂肪变性的可行性分析.临床肝胆病杂志,2017,33(06):1096-1100.
[28] 王彦华.慢性丙肝合并脂肪肝抗病毒临床治疗效果分析.中外医疗,2017,36(16):46-47+50.
[29] 张慧敏.脂肪肝和丙肝病毒(HCV)感染发病的相关性研究.中外医疗,2016,35(33):31-33.
[30] 罗莹,赵文霞.慢性丙型肝炎合并脂肪肝的中西医研究进展.中医研究,2016,29(05):76-78.
[31] 魏芳芳,张晓红.慢性丙型肝炎合并脂肪肝的发病机制.临床肝胆病杂志,2015,31(02):288-290.
[32] 曹文玺,丁虹,王新国,等.慢性丙型肝炎合并非酒精性脂肪肝抗病毒疗效及其相关因素.世界华人消化杂志,2014,22(16):2323-2326.
[33] 张威,张帆,王喜梅.壳脂胶囊联合干扰素治疗合并非酒精性脂肪性肝病的丙型肝炎患者.胃肠病学和肝病学杂志,2013,22(03):224-225.
[34] 杜飞,张锦前,郑志凌.慢性丙型肝炎合并脂肪肝血清A-FABP与病毒及代谢的相关分析.临床误诊误治,2013,26(02):68-71.
[35] 魏莉,刘江奎.脂类代谢对慢性丙型肝炎抗病毒治疗疗效的影响.中华实验和临床感染病杂志(电子版),2012,6(05):447-450. |
